Glenmark Pharmaceuticals Ltd Analyst Rating
based on 14 analysts
50.00%
Buy
35.71%
Hold
14.29%
Sell
Based on 14 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1608.07
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Share analysis
Glenmark Pharmaceuticals Ltd price forecast by 14 analysts
Upside of3.84%
High
₹2036
Target
₹1608.07
Low
₹570
Glenmark Pharmaceuticals Ltd target price ₹1608.07, a slight upside of 3.84% compared to current price of ₹1544.65. According to 14 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:29.78%
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:
Forecast
Actual
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,512.3₹1,55252 Week's Low
52 Week's High
₹771₹1,830.95
| Returns % | |
| 1 Month Return | -10.23 % |
| 3 Month Return | -9.41 % |
| 1 Year Return | + 98.79 % |
| Market Stats | |
| Previous Close | ₹1,548.65 |
| Open | ₹1,547.70 |
| Volume | 5.85L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹43,701.07Cr |
Glenmark Pharmaceuticals Ltd Key Statistics
| P/E Ratio | -49.94 |
| PEG Ratio | 1.79 |
| Market Cap | ₹43,701.07 Cr |
| P/B Ratio | 1.18 |
| EPS | -50.8 |
| Dividend Yield | 0.26 |
| Sector | Pharmaceuticals |
| ROE | 6.98 |
Glenmark Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹43,701.07 Cr | 74.49% | 0.52 | -₹1,434 Cr | ₹11,813 Cr | |
| HOLD | ₹33,069.26 Cr | 134.16% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹19,547.70 Cr | 33.06% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹7,121.95 Cr | 8.11% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹17,032.75 Cr | 54.51% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Glenmark Pharmaceuticals Ltd Mutual Fund Holdings
About Glenmark Pharmaceuticals Ltd
Share Price: ₹1544.65 per share as on 05 Dec, 2024 04:01 PM
Market Capitalisation: ₹43,701.07Cr as of today
Revenue: ₹3,400.50Cr as on September 2024 (Q3 24)
Net Profit: ₹354.49Cr as on September 2024 (Q3 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Pharmaceuticals Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Glenmark Pharmaceuticals Ltd
Glenmark Launches Travoprost Ophthalmic Solution in U.S. - 27 Nov, 2024
Glenmark Pharmaceuticals Inc. has launched Travoprost Ophthalmic Solution USP, a generic treatment for glaucoma, enhancing its portfolio in the U.S. market. The product is bioequivalent to Travatan Z, which had annual sales of approximately $66.2 million. Glenmark's U.S. portfolio now includes 200 products, with 51 ANDAs pending FDA approval.Glenmark Faces Target Price Cut After Q2 Results - 19 Nov, 2024
Glenmark Pharmaceuticals reported a net profit turnaround in Q2 FY25, but HSBC lowered its target price to ₹1,600 due to higher overheads. The company's focus remains on branded products and improving US sales through new launches and partnerships.Glenmark Reports Profit but Faces Share Decline - 18 Nov, 2024
Glenmark Pharmaceuticals returned to profitability in Q2FY25 with a net profit of Rs 354 crore, but shares fell 2.13%, leading to a market cap loss of Rs 920 crore.Glenmark Pharmaceuticals Reports Strong Q2 Results - 16 Nov, 2024
Glenmark Pharmaceuticals reported a profit of ₹354.21 crore for Q2 2024, a significant recovery from last year's loss. Revenue increased by 7.06% YoY, with a remarkable EPS rise of 3,170.53%. Despite recent challenges, analysts maintain a positive outlook, with a consensus recommendation to Buy.Glenmark Pharmaceuticals Reports Strong Q2 Turnaround - 15 Nov, 2024
Glenmark Pharmaceuticals achieved a consolidated net profit of Rs 354.49 crore in Q2 FY25, a significant recovery from a loss of Rs 180.3 crore last year. Revenue from operations increased to Rs 3,133.79 crore, with EBITDA growing by 30.2%. The company emphasizes the importance of purchasing medicines from trusted sources to combat counterfeit drugs.Glenmark Reports Strong Q2 Profit Growth - 14 Nov, 2024
Glenmark Pharmaceuticals posted a net profit of ₹354.4 crore for Q2 FY25, a significant recovery from a loss last year. Revenue increased to ₹3,433.7 crore, driven by strong performance in India and Europe. EBITDA surged 30.2%, reflecting improved margins. The company anticipates continued growth despite challenges in the North American market.Glenmark Shares Decline Ahead of Q2 FY25 Results - 13 Nov, 2024
Glenmark Pharmaceuticals shares fell over 3% to ₹1,525.75 as investors awaited Q2 FY25 earnings. Expectations include revenue of ₹3,426 crore and net profit of ₹348 crore.Glenmark Pharma Shares Recover After Initial Drop - 12 Nov, 2024
Glenmark Pharmaceuticals shares fell 10% but showed signs of recovery, trading at ₹1,614.95. Despite the dip, the stock has gained 108.1% over the past year, outperforming the BSE Healthcare index.Glenmark Shares Surge on Promising Drug Trial Results - 06 Nov, 2024
Glenmark Pharmaceuticals shares increased nearly 2% following Ichnos Glenmark Innovation's announcement of a 75% response rate for ISB 2001 in multiple myeloma patients during Phase 1 trials. The drug shows a favorable safety profile and will be presented at the ASH Annual Meeting in December 2024.
Insights on Glenmark Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.92% to 11.41% in Sep 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 20.98% to 23.05% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -1.21K Cr → 354.21 Cr (in ₹), with an average increase of 231.0% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 3.27K Cr → 3.47K Cr (in ₹), with an average increase of 5.7% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 46.65% of holdings in Sep 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 1 month, GLENMARK stock has moved down by -10.2%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 18.41% to 17.06% in Sep 2024 quarter
Glenmark Pharmaceuticals Ltd Financials
Index Inclusions
Glenmark Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.65% | 0.00 | |
| Foreign Institutions | 23.05% | 9.84 | |
| Mutual Funds | 11.41% | 4.51 | |
| Retail Investors | 17.06% | ||
| Others | 1.84% |
Glenmark Pharmaceuticals Ltd Key Indicators
Glenmark Pharmaceuticals Ltd Valuation
Glenmark Pharmaceuticals Ltd in the last 5 years
Lowest (-275.05x)
December 28, 2023
Today (-49.94x)
December 4, 2024
Industry (57.42x)
December 4, 2024
Highest (95.94x)
September 14, 2023
Glenmark Pharmaceuticals Ltd Earnings and Dividends
Glenmark Pharmaceuticals Ltd Earnings Results
Glenmark Pharmaceuticals Ltd’s net profit jumped 532.23% since last year same period to ₹354.21Cr in the Q2 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated 4.1% jump in its net profits since last 3-months.
Read More about Earnings ResultsGlenmark Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.16%.
Read More about Dividends
Glenmark Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Glenmark Pharmaceuticals Ltd is currently in a Neutral trading position according to technical analysis indicators.
FAQs on Glenmark Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Glenmark Pharmaceuticals Ltd shares.
Glenmark Pharmaceuticals Ltd (GLENMARK) share price today is ₹1544.65
Glenmark Pharmaceuticals Ltd is listed on NSE
Glenmark Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Glenmark Pharmaceuticals Ltd is ₹1552.
- Today’s lowest price of Glenmark Pharmaceuticals Ltd is ₹1512.3.
PE Ratio of Glenmark Pharmaceuticals Ltd is -49.94
PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 5.85L.
Today’s market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹43701.07Cr.
| Glenmark Pharmaceuticals Ltd(GLENMARK | Price |
|---|---|
52 Week High | ₹1830.95 |
52 Week Low | ₹771 |
Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1544.65. It is down -15.64% from its 52 Week High price of ₹1830.95
Glenmark Pharmaceuticals Ltd(GLENMARK) share price is ₹1544.65. It is up 100.34% from its 52 Week Low price of ₹771
| Glenmark Pharmaceuticals Ltd(GLENMARK | Returns |
|---|---|
1 Day Returns | -4% |
1 Month Returns | -10.23% |
3 Month Returns | -9.41% |
1 Year Returns | 98.79% |